Taipei Medical University Institutional Repository:Item 987654321/54250
English  |  正體中文  |  简体中文  |  Items with full text/Total items : 45073/58249 (77%)
Visitors : 2390060      Online Users : 157
RC Version 7.0 © Powered By DSPACE, MIT. Enhanced by NTU Library IR team.
Scope Tips:
  • please add "double quotation mark" for query phrases to get precise results
  • please goto advance search for comprehansive author search
  • Adv. Search
    HomeLoginUploadHelpAboutAdminister Goto mobile version
    Please use this identifier to cite or link to this item: http://libir.tmu.edu.tw/handle/987654321/54250


    Title: 開發PE092002肝癌治療新藥
    Newly Developed PE092002 as Molecular Therapy for Hepatocellular carcinoma (HCC)
    Authors: 謝玲珊
    Tse, Ling-Shan
    Keywords: 肝腫瘤;異位移植;去穩定化的試劑;HCC;xenograft;microtubule destabilizing agents
    Date: 2013-07-02
    Issue Date: 2018-11-20 09:37:37 (UTC+8)
    Abstract: 中文摘要

    Hepatocellular carcinoma, HCC即原發性惡性肝腫瘤,為目前最常見的肝癌類型。全球男性癌症十大死因之中,肝癌排行第二名,女性則排行第六名。而根據台灣衛生署公佈2010年及2011年的十大死因之中,肝癌在所有癌症死因中排行第二名,屬台灣之國病。然而標靶治療藥物於晚期肝癌的治療成效經長期的努力雖已漸露曙光,但礙於差強人意的療效但副作用低與病患耐受性佳的特性,亦要合併使用化學藥物或是併用多重標靶藥物。如臨床上唯一被認可可以治療肝癌的藥物Sorafenib,的確可以使肝腫瘤縮小,但只有2至3%,而整體存活時間的延長也只差強人意。因此研發更有效但副作用較低的肝癌用藥並可預防早期肝癌術後復發的用藥是急需要的。根據本研究將人類肝癌細胞株 (Hep3B及HUH-7)以皮下注射的方式分別進行小鼠異位移植實驗,於引發肝腫瘤的產生後,發現雖然Hep 3B 及HUH-7皆是以人類肝癌細胞,而且從病理切片中得知兩者皆有高度的有絲分裂,但不論由外觀及腫瘤剖開後之內觀皆可以看到其腫瘤的型態有明顯的差異。由於肝臟是血管以及血流量最多之臟器之一,兩種肝癌細胞所誘發出來的腫瘤特性相較之下,Huh-7所誘發的腫瘤較適合探討血管新生之抗癌機制。因此,在進行以下實驗時,先選用了huh-7之腫瘤進行實驗。在本研究的結果顯示連續管餵給予5mg/kg的PE092002其TGD的效果就與腹腔注射4.986mg/kg Docetaxel相近;連續管餵給予1mg/kg的PE092002其TGD的效果甚至比連續管餵給予82.08mg/kg Sorafenib好。因此我們推斷PE092002在雄性小鼠的有效劑量為5mg/kg。再以現有的數據,初步計算出其ED50為8.4664 mg/kg。由於雄小鼠口服其LD50為100mg/kg,因此,雄性小鼠之治療性指數(therapeutic index(TI))為11.81。另外,在離體細胞實驗當中我們發現PE092002會使Huh-7細胞株Bcl-2 家族中的Bid表現量上升並使Bcl-2表現量下降,使之有apoptosis的現象。同時,PE092002會使Huh-7停留在G2/M期,並促進Cyclin B1及CDK1並抑制tubulin polymerization promoting protein(TPPP)的表現量,使紡錘體無法形成。另外,PE092002亦會促使MAPK Kinase(ERK1/2、p38及JNK)與AKT之蛋白質磷酸化,此作用轉機和市面上之去穩定化的藥物 (microtubule destabilizing agents)—Vinorelbine相似。與此同時,由之前的kinase panel結果得知PE092002會使insulin receptor產生抑制的效果,而在本研究當中,當Huh-7經處理PE092002後也有抑制IGF-1R之活化的情形。由於在生成的同時IGF-1R會與各種的Pro-angiogenic proteins產生交互作用, 其中一個Angiogenic growth factors為VEGF。因此PE092002除了調控細胞分裂之外可能亦具有anti-angiogensis 的作用。根據本研究結果以及綜合前人的資料,PE092002是一個令人期待的化合物。

    Abstract
    Primary malignant liver tumor is the most common type of liver cancer and the lending cause of cancer-related death worldwide (male ranked second and female ranked sixth). Besides, HCC is the second largest cause of cancer-related death in Taiwan. HCC had limited treatment option. However, after long-term efforts, molecular target drugs show effectiveness against the disease. Although molecular target drugs have lower side-effect and good tolerability, they still are not effective enough to use along and have to combine with chemical drugs as a treatment. For example , Sorafenib, even FDA proved it can cure HCC and shrink the liver tumor, it has only 2-3% effectiveness. Besides the overall survival time prolonged only passably. Therefore, development of a high effective and low side-effect anti-HCC drug is must and pressing. In this study, we injected human hepatoma cell line (Hep3B ,HUH-7) subcutaneously in CB17 SCID mice to induce tumor. Although we found that both tumors produced high degree of mitosis, both tumors obviously were different in appearance and pattern. Since liver is one of organs which has the most fully blood vessels distributed and highly blood flow, with respect to the tumor induced by Hep 3B and HUH-7, HUH-7 tumor has higher angiogenic amount potential more than Hep 3B tumor. Therefore, we chose HUH-7 to continue the following study. The results showed that when mouse were orally-administered drugs PE092002 5mg/kg/day , its tumor growth delay(TGD) was similar to Docetaxel 4.986mg/kg ip once. Moreover, when mouse were orally-administered drugs PE092002 1mg/kg/day, its tumor growth delay (TGD) was much better than orally-administered drugs Sorafenib 82.08mg/kg/day. Therefore, we assumed the effective dose of PE092002 as 5mg/kg at male mice. as prior study ,we found that the LD50 of PE092002 on male mice was 100mg/kg. Then we calculated the ED50 and therapeutic index (TI) as 8.4664/mg/kg and 11.81. In our in vitro studies of PE092002 in Huh-7, we found that PE092002 could upregulate the Bid and down regulate the Bcl-2 which are in the Bcl-2 family to induce apoptosis. At the meanwhile, PE092002 could also cause G2/M arrest, upregulating Cyclin B1 and CDK1. Furthermore PE092002 could also downregulate the expression of tubulin polymerization promoting protein (TPPP) to suppress the spindle formation. PE092002 could also increase the phosphorylation of MAPK Kinase (ERK1/2、p38及JNK) and AKT in Huh-7. Those effects showed the mechanism of PE092002 is similar to the microtubule destabilizing agents—Vinorelbine. According to the Kinase panel result, PE092002 is able to suppress the insulin receptor. In our study, also found PE092002 could downregulate the phosphorylation of IGF-1R in Huh-7. Because of IGF-1R would cause interaction with some angiogenic growth factors, like VEGF. So, we also assumed PE092002 may not only be able to cause apoptosis but also may cause anti- angiogenesis effect. In conclusion all the results of PE092002, PE092002 is a prospective compound.
    Description: 碩士
    指導教授-鄭幼文
    委員-王惠珀
    委員-康照洲
    Data Type: thesis
    Appears in Collections:[School of Pharmacy] Dissertation/Thesis

    Files in This Item:

    File Description SizeFormat
    index.html0KbHTML197View/Open


    All items in TMUIR are protected by copyright, with all rights reserved.


    著作權聲明 Copyright Notice
    • 本平台之數位內容為臺北醫學大學所收錄之機構典藏,包含體系內各式學術著作及學術產出。秉持開放取用的精神,提供使用者進行資料檢索、下載與取用,惟仍請適度、合理地於合法範圍內使用本平台之內容,以尊重著作權人之權益。商業上之利用,請先取得著作權人之授權。

      The digital content on this platform is part of the Taipei Medical University Institutional Repository, featuring various academic works and outputs from the institution. It offers free access to academic research and public education for non-commercial use. Please use the content appropriately and within legal boundaries to respect copyright owners' rights. For commercial use, please obtain prior authorization from the copyright owner.

    • 瀏覽或使用本平台,視同使用者已完全接受並瞭解聲明中所有規範、中華民國相關法規、一切國際網路規定及使用慣例,並不得為任何不法目的使用TMUIR。

      By utilising the platform, users are deemed to have fully accepted and understood all the regulations set out in the statement, relevant laws of the Republic of China, all international internet regulations, and usage conventions. Furthermore, users must not use TMUIR for any illegal purposes.

    • 本平台盡力防止侵害著作權人之權益。若發現本平台之數位內容有侵害著作權人權益情事者,煩請權利人通知本平台維護人員([email protected]),將立即採取移除該數位著作等補救措施。

      TMUIR is made to protect the interests of copyright owners. If you believe that any material on the website infringes copyright, please contact our staff([email protected]). We will remove the work from the repository.

    Back to Top
    DSpace Software Copyright © 2002-2004  MIT &  Hewlett-Packard  /   Enhanced by   NTU Library IR team Copyright ©   - Feedback